Therapeutic Effects of Methylprednisolone on Clinical Symptoms in COVID-19 Patients at Dr. R. Goeteng Taroenadibrata Hospital
Abstract
COVID-19 is a respiratory syndrome disease in humans caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until now, treatment for COVID-19 has not been found. This study aimed to observed a therapeutic effect of methylprednisolone in COVID-19 patients. Medical records of COVID-19 patients at dr. R. Goeteng Taroenadibrata Purbalingga Hospital were collected retrospectively as part of this descriptive observational study from October 2020 to September 2021. Utilizing the Wilcoxon and Sign Test, a statistical analysis was conducted to determine the therapeutic effect of methylprednisolone on variables such as temperature, respiratory rate, oxygen saturation, cough, and shortness of breath. A total of 132 patients met the inclusion criteria, with 87 patients in mild severity, 22 patients with moderate severity, and 23 patients with severe severity. The clinical symptoms of cough, dyspnea, RR values, and SpO2 improved when methylprednisolone was given to mild COVID-19 patients receiving treatment at RSUD dr. R. Goeteng Taroenadibrata Purbalingga. Additionally, clinical symptoms related to cough, SpO2, and temperature parameters improved in patients with moderate severity; in contrast, breathlessness, respiratory distress, SpO2, and temperature parameters improved in patients with severe severity. In conclusion, Goeteng Taroenadibrata Hospital COVID-19 patients report improved clinical symptoms when receiving methylprednisolone.
Keywords
Full Text:
PDFReferences
Izda V, Jeffries MA, and Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin. Immunol. 2021;222:108634.
World Health Organization. COVID-19 Weekly Epidemiological Update Edition 134. World Health Organization; 16 Mar 2023 (accessed on 12 Sep 2023). Available at: https://iris.who. int/bitstream/handle/10665/366534/ nCoV-weekly-sitrep16Mar23-eng. pdf?sequence=1.
Williams DM. Clinical Pharmacology of Corticosteroids. Respir. Care. 2018;63(6): 655–670.
Liberman AC, Budziñski ML, Sokn C, Gobbini RP, Steininger A, and Arzt E. Regulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells. Front. Endocrinol. 2018;9:235.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. Guideline for the Management of COVID-19. 3rd Edition. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI); 2020.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. Guideline for the Management of COVID-19. 4th Edition. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia; 2022.
Yang R, Xiong Y, Ke H, Chen T, Gao S. The Role of Methylprednisolone on Preventing Disease Progression for Hospitalized Patients with Severe COVID‐19. European Journal of Clinical Investigation. 2020;50(11):e13412.
Zanella A, Paraskevopoulos DK, de Lima Galvao DK, and Yamaguti LA. Methylprednisolone Pulse Therapy in COVID-19 as the First Choice for Public Health: When Right Timing Breaks Controversies-Emergency Guide. Open J. Emerg. Med. 2021;9:84-114.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514– 23.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395 (10223):497–506.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239–42.
Sanjaya K, Paramita S, Khalidi MR. Epidemiology of Characteristics of COVID-19 Patients in Kutai Kartanegara in July-December 2020. J Sains dan Kesehatan. 2021; 3(6):876–84.
Wasityastuti W, Dhamarjati A, Siswanto. Imunosenesens dan Kerentanan Populasi Usia Lanjut Terhadap Coronavirus Disease 2019 (COVID-19). Respirologi Indonesia. 2019;40(3):182–191.
Agustiyah L, Ronoatmodjo S. Characteristics of Patients Confirmed COVID-19 at Al-Mulk Hospital, Sukabumi on September 2020–June 2021. Journal of Nursing and Midwifery. 2021;231:158–169.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal. 2020;55(4).
Kronbichler A, Effenberger M, Eisenhut M, Lee KH, Shin JI. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. Autoimmunity Reviews. 2020;19:102570. doi: 10.1016/j. autrev.2020.102570
Hariharan A, Hakeem AR; Radhakrishnan S, Reddy MS, Rela M. The Role and Therapeutic Potential of NF kappa B Pathway in Severe COVID 19 Patients. Inflammopharmacology. 2021;29(1):91- 100. doi: 10.1007/s10787-020-00773-9.
Dabija RC., Antohe I., Trofor A., Antoniu SA. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. Expert Rev Anti Infect Ther . 2021;9(12):1553-1562. doi: 10.1080/14787210.2021.1933437
Al Meslamani AZ, Kassem AB, El- Bassiouny NA., Ibrahim OM. An emergency plan for management of COVID-19 patients in rural areas. Int J Clin Pract. 2021;75(10): e14563. doi: 10.1111/ijcp.14563
BPOM. Informatorium of COVID-19 Drugs in Indonesia. Edisi-4. Jakarta: Badan Pengawas Obat dan Makanan Indonesia, 2020.
Ardyati S, Kurniawan NU, Darmawan E. The Effect of Steroid Administration as Additional Therapy on the Average Length of Patient Hospitalization and Clinical Signs in Children with Pneumonia. Indonesian Journal of Clinical Pharmacy. 2017;6 (3):181-189.
DOI: https://doi.org/10.15416/ijcp.2024.13.1.1
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
